Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

BET Bromodomain Inhibition Selectively Targets the Epstein-Barr Virus Oncogene LMP1 While Promoting Virus-Specific, Adaptive Anti-Tumor Activity

Emily Smith, Andrew Stiff, BS, John T. Patton, PhD, William Carson, III, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 46.

https://doi.org/10.1182/blood.V128.22.46.46

Published: 2016

Journal Articles

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

Porsha L. Smith, PhD, Fengting Yan, MD PhD, John T. Patton, PhD, Lapo Alinari, MD PhD, Vrajesh Karkhanis, PhD, Leona Ayers, MD, Natarajan Muthusamy, DVM, PhD, Anjali Mishra, PhD, Elshafa Ahmed, DVM, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 2936.

https://doi.org/10.1182/blood.V128.22.2936.2936

Published: 2016

Journal Articles

Identifying and Targeting Cytotoxic Tumor-Associated Macrophages in Epstein-Barr Virus-Driven Lymphoproliferative Disease

John T. Patton, PhD, Monica L Mitchell, Li Pan, PhD, A. Douglas Kinghorn, PhD, D.Sc, Michael R. Grever, MD, David M. Lucas, PhD, Robert A. Baiocchi, MD PhD

Blood (2014) 124 (21): 4489.

https://doi.org/10.1182/blood.V124.21.4489.4489

Published: 2014

Journal Articles

Determination of Optimal Target Antigen and Immune Modulatory Approaches to Improve and Standardize Epstein-Barr Virus-Specific Adoptive T Cell Therapy

Monica L Mitchell, John T. Patton, PhD, Lynn O'Donnell, PhD, Robert A. Baiocchi, MD PhD

Blood (2014) 124 (21): 5817.

https://doi.org/10.1182/blood.V124.21.5817.5817

Published: 2014

Journal Articles

Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder

James Dugan, MD MS, Bradley M. Haverkos, MD MPH, Ludmila Katherine Martin, MD, Marisa F. Martin, Mark E Lustberg, MD PhD, John T. Patton, PhD, Gerard Nuovo, MD, Fengting Yan, MD, PhD, Robert Cavaliere, MD, Shannon C. Kenney, MD, Joyce Fingeroth, MD, Gerard Lozanski, MD, Juan Carlos Ramos, MD, Pierluigi Porcu, MD, Michael A. Caligiuri, MD, Robert A. Baiocchi, MD PhD

Blood (2014) 124 (21): 1750.

https://doi.org/10.1182/blood.V124.21.1750.1750

Published: 2014

Journal Articles

Novel E-Selectin Antagonist GMI-1271 Decreases Venous Thrombosis without Increased Bleeding Potential in a Mouse Model

Daniel Durant Myers, Jr., DVM, MPH, Dorian L Culmer, DVM, Jose A. Diaz, MD, Angela E. Hawley, MS, Peter K. Henke, MD, Suman L. Sood, MD, Robert E Sigler, DVM, PhD, Andrea T Obi, MD, John T. Patton, PhD, Thomas W. Wakefield, MD, John L. Magnani, PhD

Blood (2012) 120 (21): 3422.

https://doi.org/10.1182/blood.V120.21.3422.3422

Published: 2012

Journal Articles

A Novel Small Molecule E-Selectin Inhibitor GMI-1271 Blocks Adhesion of AML Blasts to E-Selectin and Mobilizes Blood Cells in Nodscid IL2Rgc −/− Mice Engrafted with Human AML

Sylvia Chien, Xin Zhao, MD, Margaret Brown, Akanksha Saxena, BS, John T. Patton, PhD, John L. Magnani, PhD, Pamela S Becker, MD, PhD

Blood (2012) 120 (21): 4092.

https://doi.org/10.1182/blood.V120.21.4092.4092

Published: 2012

Journal Articles

Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State

John L. Magnani, PhD, Frans A Kuypers, PhD, John T. Patton, PhD, Sandra K Larkin, MS, Lori Styles, MD, Laura M DeCastro, MD, Marilyn J. Telen, MD, Ted Wun, MD, Helen Thackray, MD

Blood (2012) 120 (21): 87.

https://doi.org/10.1182/blood.V120.21.87.87

Published: 2012

Journal Articles

Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc−/− Xenograft and Confer Susceptibility to Cytarabine

Sylvia Chien, Xin Zhao, MD, John T. Patton, PhD, Theodore Smith, Arun Sarkar, PhD, John L. Magnani, Frederick R. Appelbaum, MD, Pamela S Becker, MD, PhD

Blood (2011) 118 (21): 579.

https://doi.org/10.1182/blood.V118.21.579.579

Published: 2011

Journal Articles

Pan-Selectin Antagonist, GMI-1070 Decreases Venous Thrombosis in a Mouse Model,

Daniel Durant Myers, Jr., DVM, MPH, Peter K. Henke, MD, Jose A. Diaz, MD, Shirley K. Wrobleski, BS, Angela E. Hawley, MS, Dallas Slack, BS, Thomas W. Wakefield, MD, John T. Patton, PhD, John L. Magnani

Blood (2011) 118 (21): 3273.

https://doi.org/10.1182/blood.V118.21.3273.3273

Published: 2011

NARROW

BET Bromodomain Inhibition Selectively Targets the Epstein-Barr Virus Oncogene LMP1 While Promoting Virus-Specific, Adaptive Anti-Tumor Activity

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

Identifying and Targeting Cytotoxic Tumor-Associated Macrophages in Epstein-Barr Virus-Driven Lymphoproliferative Disease

Determination of Optimal Target Antigen and Immune Modulatory Approaches to Improve and Standardize Epstein-Barr Virus-Specific Adoptive T Cell Therapy

Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder

Novel E-Selectin Antagonist GMI-1271 Decreases Venous Thrombosis without Increased Bleeding Potential in a Mouse Model

A Novel Small Molecule E-Selectin Inhibitor GMI-1271 Blocks Adhesion of AML Blasts to E-Selectin and Mobilizes Blood Cells in Nodscid IL2Rgc −/− Mice Engrafted with Human AML

Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State

Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc−/− Xenograft and Confer Susceptibility to Cytarabine

Pan-Selectin Antagonist, GMI-1070 Decreases Venous Thrombosis in a Mouse Model,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only